ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2016

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

S Loibl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.